Hospira Docetaxel

In combination w/ doxorubicin for patients w/ locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy; monotherapy for locally advanced or metastatic breast cancer after failure of cytotoxic therapy. In combination w/ capecitabine for locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Locally advanced or metastatic NSCLC after failure of prior chemotherapy. In combination w/ cisplatin for unresectable, locally advanced or metastatic NSCLC in patients who have not previously received chemotherapy for this condition. In combination w/ prednisone or prednisolone for hormone refractory metastatic prostate cancer. In combination w/ cisplatin & 5-fluorouracil for metastatic gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction in patients who have not received prior chemotherapy for metastatic disease. Induction treatment in combination w/ cisplatin & 5-fluorouracil for inoperable locally advanced squamous cell carcinoma of the head & neck (SCCHN). Metastatic carcinoma of the ovary after failure of 1st-line or subsequent chemotherapy.

Breast, non-small cell lung, ovarian, gastric, head & neck cancer Premedication: Oral corticosteroid eg, dexamethasone 16 mg daily for 3 days starting 1 day prior to docetaxel administration. Prostate cancer Premedication: Oral dexamethasone 8 mg 12 hr, 3 hr & 1 hr before docetaxel infusion. IV Locally advanced or metastatic breast cancer Monotherapy: 100 mg/m² as 1 hr infusion every 3 wk. 1st-line treatment: 75 mg/m² in combination w/ doxorubicin 50 mg/m². In combination w/ capecitabine: Docetaxel 75 mg/m² every 3 wk & capecitabine 1,250 mg/m² bd for 2 wk followed by 1-wk rest period. NSCLC (chemotherapy-naïve) 75 mg/m² immediately followed by cisplatin 75 mg/m² over 30-60 min. After failure of prior platinum-based treatment: 75 mg/m² as a single agent. Prostate cancer 75 mg/m² as 1 hr infusion every 3 wk. Prednisone or prednisolone 5 mg orally bd. Gastric adenocarcinoma 75 mg/m² as 1 hr infusion, followed by cisplatin 75 mg/m² as 1-3 hr infusion (both on day 1), followed by 5-fluorouracil 750 mg/m² daily as 24 hr continuous infusion for 5 days starting at the end of cisplatin infusion. Repeated every 3 wk. Inoperable locally advanced SCCHN Induction: 75 mg/m² as 1 hr infusion, followed by cisplatin 75 mg/m² over 1 hr on day 1, followed by 5-fluorouracil as continuous infusion at 750 mg/m² daily for 5 days. Administer every 3 wk for 4 cycles. Locally advanced SCHHN Induction: 75 mg/m² as 1 hr IV infusion on day 1, followed by cisplatin 100 mg/m² as 30 min to 3 hr infusion followed by 5-fluorouracil 1,000 mg/m² daily as continuous infusion from day 1-4. Administer every 3 wk for 3 cycles. Ovarian cancer 100 mg/m² as 1 hr infusion every 3 wk.

Hypersensitivity. Baseline neutrophil count <1,500 cells/mm³. Combination w/ other medicinal products. Severe liver impairment. Pregnancy & lactation.

Cytotoxic Chemotherapy

L01CD02 - docetaxel ; Belongs to the class of taxanes from plant alkaloids and other natural products. Used in the treatment of cancer.

POM